Imperial Bioscience
Biopharmaceutical company developing and commercialising dissolving microneedle (microarray patch) technologies for transdermal delivery of cosmeceutical and pharmaceutical actives. The organisation focuses on R&D of hyaluronic acid–based self‑dissolving microstructures, manufacturing processes for microarray patches, clinical evaluation of patch efficacy, and commercialisation of skincare product lines. The company publishes clinical studies and has received public translational R&D funding to progress preclinical programmes toward clinical stages.
Industries
Nr. of Employees
small (1-50)
Imperial Bioscience
The Shard, 25 Floor, 32 London Bridge St, London SE1 9SG, UK
Products
Cosmetic microneedle patch product line (consumer skincare kits)
Consumer-facing dissolving microneedle patch kits formulated with vegAN-friendly actives and hyaluronic acid–based micro‑structures to address skin concerns such as fine lines, hyperpigmentation, blemishes and scarring.
Cosmetic microneedle patch product line (consumer skincare kits)
Consumer-facing dissolving microneedle patch kits formulated with vegAN-friendly actives and hyaluronic acid–based micro‑structures to address skin concerns such as fine lines, hyperpigmentation, blemishes and scarring.
Services
Platform development and partnership/licensing opportunities to adapt dissolving microneedle patches for different active ingredients and indications.
Platform development and partnership/licensing opportunities to adapt dissolving microneedle patches for different active ingredients and indications.
Expertise Areas
- Transdermal drug delivery
- Microneedle/microarray patch development
- Formulation of biomolecules for transdermal delivery
- Cosmeceutical product development
Key Technologies
- Dissolving microneedle / microarray patch platforms
- Hyaluronic acid–based dissolvable microstructures
- Droplet‑extension (DEN) microfabrication for patches
- Encapsulation and stabilization of peptides and biomolecules in patch matrices
News & Updates
Finalist nomination in the Innovator of the Year category at the Growing Business Awards 2023.
Shortlisted as a finalist in the Barclays Entrepreneur Awards 2023, Eagle Labs Innovation Award category.
Awarded a Biomedical Catalyst grant from Innovate UK to support preclinical development and progression toward clinical testing (grant amount reported as £0.5 million).
Clinical study (May 28 2019) investigating efficacy of bioactive peptides loaded onto hyaluronic acid microneedle patches for ageing skin.
Clinical study (July 21 2020) on dissolvable microneedles with anti‑melanogenic compounds for hyperpigmentation.
Review article discussing advances and challenges in microneedle transdermal delivery technologies.
Finalist nomination in the Innovator of the Year category at the Growing Business Awards 2023.
Shortlisted as a finalist in the Barclays Entrepreneur Awards 2023, Eagle Labs Innovation Award category.
Awarded a Biomedical Catalyst grant from Innovate UK to support preclinical development and progression toward clinical testing (grant amount reported as £0.5 million).
Clinical study (May 28 2019) investigating efficacy of bioactive peptides loaded onto hyaluronic acid microneedle patches for ageing skin.
Clinical study (July 21 2020) on dissolvable microneedles with anti‑melanogenic compounds for hyperpigmentation.
Review article discussing advances and challenges in microneedle transdermal delivery technologies.